7 Best Pharmaceutical Stocks To Invest In Now For A Profitable 2022

December 6, 2022 Staff Reporter 2851 Views 0 Comments

Are you looking to make a lucrative investment in the pharmaceutical industry? With 2021 fast approaching, now is the perfect time to consider investing in one of the best pharmaceutical stocks for a profitable 2022. Pharmaceutical stocks have historically offered investors the chance to make returns that outperform the overall market, making them an attractive option for investors. From large pharmaceutical companies to small-cap stocks, the choices are plentiful when it comes to investing in the right pharmaceutical stocks. To help you make a smarter decision, we’ve compiled a list of the 7 best pharmaceutical stocks to invest in now for a profitable 2022. With this guide, you can explore the best stocks in the industry and make an informed decision when it comes to your investment. Let’s take a closer look at the 7 best pharmaceutical stocks to invest in now for a profitable 2022.

What Are The Benefits of Investing in Pharmaceutical Stocks?

Investing in the pharmaceutical industry can be a lucrative option for investors, thanks to its strong track record. According to data from S&P Capital IQ, the pharmaceutical sector has historically outperformed the S&P 500, making it an attractive option for investors. In fact, the sector has outperformed the S&P 500 in 11 out of the last 20 years. With the pharmaceutical industry continuing to innovate and develop new drugs, the potential for pharmaceutical stocks to outperform the S&P 500 remains high. Pharmaceutical stocks also represent a diverse group of companies, making them suitable for investors of every type. From large multinational companies to small-cap stocks, the industry is home to many pharmaceutical stocks that could appeal to different types of investors.

The 7 Best Pharmaceutical Stocks To Invest In Now For A Profitable 2022

a. Johnson & Johnson

Johnson & Johnson is a multinational health care company that boasts a wide range of products, including over 250 pharmaceutical products. The company has a proven track record when it comes to producing high-quality pharmaceutical drugs, making JNJ a suitable option for investors. One of JNJ’s most profitable drugs is CAR-T therapy, which is currently being used to treat blood cancers such as leukemia. CAR-T therapy is considered a groundbreaking treatment that shows great promise in the fight against cancer. In fact, the therapy is expected to become a $50 billion industry by 2024, making it a lucrative investment opportunity. JNJ also offers other promising drugs, such as Siliq, an injectable treatment for multiple sclerosis. Overall, JNJ is a solid pharmaceutical stock that could be a profitable long-term investment.

b. Pfizer

Founded in 1849, Pfizer is a global pharmaceutical company that develops and markets both innovative biopharmaceutical and traditional medicines. The company is one of the largest pharmaceutical companies in the world, and its one-two punch of established drugs and new products could make it a lucrative investment opportunity for investors. One example of an established drug Pfizer produces is the anti-depressant drug Zoloft, which has been on the market for decades. However, it remains one of the most prescribed drugs in the world, resulting in a steady stream of revenue for Pfizer. Pfizer is also developing new drugs that could lead to even more revenue for the company. One such drug is Xeljanz, which is used as a treatment for inflammatory conditions such as rheumatoid arthritis. Xeljanz is expected to bring in $4.9 billion in revenue by 2022 and continues to be one of the top-selling drugs in the world. Overall, Pfizer is a pharmaceutical stock that could be an attractive long-term investment.

c. Merck

Merck is a global healthcare company that develops and manufactures a wide range of healthcare products. The company is one of the largest pharmaceutical companies in the world and is currently investing heavily in new drug development. One such drug is an experimental therapy for hepatitis B, which is set to be released in 2022. The drug is expected to become a billion-dollar blockbuster, thanks to the large number of people who are infected with the disease. Merck has also partnered with Heptares Therapeutics to produce an experimental therapy for Alzheimer’s disease. The drug has shown promise in early-stage testing, making it a promising investment opportunity for Merck investors. Merck is expected to bring in $74 billion in revenue in 2022 and is one of the most profitable companies in the pharmaceutical industry. Overall, Merck is a high-quality pharmaceutical stock that could be a lucrative investment for long-term investors.

d. Amgen

Headquartered in California, Amgen is a biopharmaceutical company that specializes in the discovery, development, and production of medicines. Amgen produces a wide range of products, including biologic drugs, biosimilars, and branded injectable drugs. The company also works with biopharmaceutical companies to develop biosimilars, which are less expensive versions of complex biologic drugs. Amgen is one of the largest biologic companies in the world and is expected to bring in $32 billion in revenue in 2022. One of Amgen’s top-selling biologic drugs is Neulasta, which is used to treat patients with certain types of cancer. Neulasta has been on the market for decades and is expected to bring in $7.7 billion in revenue in 2022. Although Neulasta is an established drug, Amgen’s focus on biologic drugs could lead to even more revenue in the future. Amgen is a biopharmaceutical company that could be a lucrative long-term investment.

e. Biogen

Biogen is a biopharmaceutical company headquartered in Massachusetts that specializes in the discovery and development of medicines. The company is one of the largest biopharmaceutical companies in the world and specializes in developing and selling therapies for neurological diseases. One such therapy is Spinraza, an injection therapy for spinal muscular atrophy that recently received FDA approval. Spinraza is expected to become a billion-dollar drug in the near future, making it a lucrative investment. Biogen is also developing a drug that could be used to treat amyotrophic lateral sclerosis (ALS). The drug, known as Gantner, is showing promise in early-stage testing and is expected to reach the market in 2022. Overall, Biogen is a biopharmaceutical company that is expected to bring in $22 billion in revenue in 2022 and could be a lucrative investment opportunity for long-term investors.

f. Gilead Sciences

Headquartered in California, Gilead Sciences is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines. The company’s focus on developing new drugs for diseases such as hepatitis B, HIV, and certain types of cancers has resulted in high-quality products and steady revenue for the company. Gilead Sciences is expected to bring in $28 billion in revenue in 2022, making it one of the most profitable pharmaceutical companies in the world. Gilead is known for producing the therapies Sovaldi and Harvoni, which are used to treat hepatitis C. The drugs are considered to be the gold standard in treatment for hepatitis C and are expected to generate $25 billion in revenue in 2022. Gilead Sciences is a biopharmaceutical company that could be a lucrative long-term investment, thanks to its high-quality products and steady revenue.

g. AbbVie

AbbVie is a biopharmaceutical company headquartered in Illinois that produces medicines and vaccines for a wide range of diseases. The company specializes in developing therapies for autoimmune diseases and cancer, and it currently holds the No. 1 spot in biotechnology companies. AbbVie is expected to bring in $32 billion in revenue in 2022, making it one of the most profitable biotechnology companies in the world.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source